vs
奥尼兰姆制药（ALNY）与RANGE RESOURCES CORP（RRC）财务数据对比。点击上方公司名可切换其他公司
奥尼兰姆制药的季度营收约是RANGE RESOURCES CORP的1.5倍（$1.2B vs $786.9M），RANGE RESOURCES CORP净利率更高（22.8% vs 17.6%，领先5.1%），奥尼兰姆制药同比增速更快（96.4% vs 18.0%），过去两年奥尼兰姆制药的营收复合增速更高（33.0% vs 14.6%）
奥尼兰姆制药是美国生物制药企业，2002年成立，总部位于马萨诸塞州剑桥市，专注于研发及商业化针对基因明确疾病的RNA干扰（RNAi）疗法，2016年入选福布斯「100家最具创新力成长企业」榜单。
Range Resources Corporation是一家总部位于美国得克萨斯州沃斯堡的天然气勘探开采企业，核心运营区域为马塞勒斯页岩地层，是该地区拥有土地面积最大的运营商，专注于天然气资源的勘探、开发与生产业务，在北美油气开发领域具备深厚的行业积累。
ALNY vs RRC — 直观对比
营收规模更大
ALNY
是对方的1.5倍
$786.9M
营收增速更快
ALNY
高出78.5%
18.0%
净利率更高
RRC
高出5.1%
17.6%
两年增速更快
ALNY
近两年复合增速
14.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $786.9M |
| 净利润 | $206.0M | $179.1M |
| 毛利率 | 82.2% | 94.5% |
| 营业利润率 | 23.0% | — |
| 净利率 | 17.6% | 22.8% |
| 营收同比 | 96.4% | 18.0% |
| 净利润同比 | — | 88.8% |
| 每股收益（稀释后） | $1.51 | $0.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALNYRRC
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.1B | $786.9M | ||
| Q3 25 | $1.2B | $655.3M | ||
| Q2 25 | $773.7M | $699.6M | ||
| Q1 25 | $594.2M | $846.3M | ||
| Q4 24 | $593.2M | $667.0M | ||
| Q3 24 | $500.9M | $567.9M | ||
| Q2 24 | $659.8M | $513.2M |
净利润ALNYRRC
| Q1 26 | $206.0M | — | ||
| Q4 25 | $186.4M | $179.1M | ||
| Q3 25 | $251.1M | $144.3M | ||
| Q2 25 | $-66.3M | $237.6M | ||
| Q1 25 | $-57.5M | $97.1M | ||
| Q4 24 | $-83.8M | $94.8M | ||
| Q3 24 | $-111.6M | $50.7M | ||
| Q2 24 | $-16.9M | $28.7M |
毛利率ALNYRRC
| Q1 26 | 82.2% | — | ||
| Q4 25 | 75.6% | 94.5% | ||
| Q3 25 | 84.2% | 92.5% | ||
| Q2 25 | 81.6% | 95.0% | ||
| Q1 25 | 88.2% | 93.1% | ||
| Q4 24 | 82.7% | 93.7% | ||
| Q3 24 | 83.6% | 94.3% | ||
| Q2 24 | 89.8% | 93.4% |
营业利润率ALNYRRC
| Q1 26 | 23.0% | — | ||
| Q4 25 | 12.0% | — | ||
| Q3 25 | 29.5% | — | ||
| Q2 25 | -2.1% | — | ||
| Q1 25 | 3.0% | — | ||
| Q4 24 | -17.7% | — | ||
| Q3 24 | -15.4% | — | ||
| Q2 24 | 7.4% | — |
净利率ALNYRRC
| Q1 26 | 17.6% | — | ||
| Q4 25 | 17.0% | 22.8% | ||
| Q3 25 | 20.1% | 22.0% | ||
| Q2 25 | -8.6% | 34.0% | ||
| Q1 25 | -9.7% | 11.5% | ||
| Q4 24 | -14.1% | 14.2% | ||
| Q3 24 | -22.3% | 8.9% | ||
| Q2 24 | -2.6% | 5.6% |
每股收益（稀释后）ALNYRRC
| Q1 26 | $1.51 | — | ||
| Q4 25 | $1.44 | $0.75 | ||
| Q3 25 | $1.84 | $0.60 | ||
| Q2 25 | $-0.51 | $0.99 | ||
| Q1 25 | $-0.44 | $0.40 | ||
| Q4 24 | $-0.66 | $0.38 | ||
| Q3 24 | $-0.87 | $0.21 | ||
| Q2 24 | $-0.13 | $0.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.7B | $204.0K |
| 总债务越低越好 | — | $1.2B |
| 股东权益账面价值 | $1.1B | $4.3B |
| 总资产 | $5.1B | $7.4B |
| 负债/权益比越低杠杆越低 | — | 0.28× |
8季度趋势，按日历期对齐
现金及短期投资ALNYRRC
| Q1 26 | $1.7B | — | ||
| Q4 25 | $1.7B | $204.0K | ||
| Q3 25 | $1.5B | $175.0K | ||
| Q2 25 | $1.1B | $134.0K | ||
| Q1 25 | $1.0B | $344.6M | ||
| Q4 24 | $966.4M | $304.5M | ||
| Q3 24 | $1.1B | $277.4M | ||
| Q2 24 | $968.5M | $251.1M |
总债务ALNYRRC
| Q1 26 | — | — | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | — | $1.7B |
股东权益ALNYRRC
| Q1 26 | $1.1B | — | ||
| Q4 25 | $789.2M | $4.3B | ||
| Q3 25 | $233.9M | $4.2B | ||
| Q2 25 | $250.6M | $4.1B | ||
| Q1 25 | $115.4M | $3.9B | ||
| Q4 24 | $67.1M | $3.9B | ||
| Q3 24 | $32.4M | $3.9B | ||
| Q2 24 | $-3.1M | $3.9B |
总资产ALNYRRC
| Q1 26 | $5.1B | — | ||
| Q4 25 | $5.0B | $7.4B | ||
| Q3 25 | $4.9B | $7.2B | ||
| Q2 25 | $4.6B | $7.1B | ||
| Q1 25 | $4.2B | $7.4B | ||
| Q4 24 | $4.2B | $7.3B | ||
| Q3 24 | $4.2B | $7.2B | ||
| Q2 24 | $4.0B | $7.3B |
负债/权益比ALNYRRC
| Q1 26 | — | — | ||
| Q4 25 | — | 0.28× | ||
| Q3 25 | — | 0.29× | ||
| Q2 25 | — | 0.29× | ||
| Q1 25 | — | 0.43× | ||
| Q4 24 | — | 0.43× | ||
| Q3 24 | — | 0.44× | ||
| Q2 24 | — | 0.44× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $257.5M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 1.44× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ALNYRRC
| Q1 26 | — | — | ||
| Q4 25 | $163.6M | $257.5M | ||
| Q3 25 | $325.1M | $247.5M | ||
| Q2 25 | $153.7M | $336.2M | ||
| Q1 25 | $-118.3M | $330.1M | ||
| Q4 24 | $-94.7M | $217.9M | ||
| Q3 24 | $43.7M | $245.9M | ||
| Q2 24 | $124.2M | $148.8M |
自由现金流ALNYRRC
| Q1 26 | — | — | ||
| Q4 25 | $140.3M | — | ||
| Q3 25 | $313.0M | — | ||
| Q2 25 | $139.4M | — | ||
| Q1 25 | $-127.3M | — | ||
| Q4 24 | $-103.8M | — | ||
| Q3 24 | $39.5M | — | ||
| Q2 24 | $116.1M | — |
自由现金流率ALNYRRC
| Q1 26 | — | — | ||
| Q4 25 | 12.8% | — | ||
| Q3 25 | 25.1% | — | ||
| Q2 25 | 18.0% | — | ||
| Q1 25 | -21.4% | — | ||
| Q4 24 | -17.5% | — | ||
| Q3 24 | 7.9% | — | ||
| Q2 24 | 17.6% | — |
资本支出强度ALNYRRC
| Q1 26 | — | — | ||
| Q4 25 | 2.1% | — | ||
| Q3 25 | 1.0% | — | ||
| Q2 25 | 1.8% | — | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 0.8% | — | ||
| Q2 24 | 1.2% | — |
现金转化率ALNYRRC
| Q1 26 | — | — | ||
| Q4 25 | 0.88× | 1.44× | ||
| Q3 25 | 1.29× | 1.72× | ||
| Q2 25 | — | 1.42× | ||
| Q1 25 | — | 3.40× | ||
| Q4 24 | — | 2.30× | ||
| Q3 24 | — | 4.85× | ||
| Q2 24 | — | 5.18× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALNY
| AMVUTTRA | $889.9M | 76% |
| GIVLAARI | $74.4M | 6% |
| OXLUMO | $51.3M | 4% |
| Royalty revenue | $49.0M | 4% |
| Regeneron Pharmaceuticals | $46.3M | 4% |
| Roche | $35.6M | 3% |
| ONPATTRO | $20.5M | 2% |
RRC
| Natural Gas Natural Gas Liquids And Oil Sales | $745.5M | 95% |
| Brokered Natural Gas And Marketing | $41.3M | 5% |
